Ribociclib: tested in a combination

57 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07826052Phase 2Report a problem
• A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingNCT07618390Phase 2Report a problem
• Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3Report a problem
• Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07005557Phase 3Report a problem
• Novel Molecular Targets and Innovative Therapeutic Perspective in MedulloblastomaRecruitingNCT06959979Early Phase 1Report a problem
• Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingNCT06849947Phase 2Report a problem
• The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicableReport a problem
• Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingNCT06656624Phase 2Report a problem
• T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationNCT06481956Phase 2Report a problem
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2Report a problem
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3Report a problem
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2Report a problem
• Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingNCT06044623Phase 3Report a problem
• Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingNCT05843253Phase 2Report a problem
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2Report a problem
• Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminatedNCT04315233Phase 1Results postedReport a problem
• Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast CancerCompletedNCT03839823Phase 2Results postedReport a problem
• A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for ResectionCompletedNCT03834740Early Phase 1Results postedReport a problem
• Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 2Results postedReport a problem
• Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT03477396Phase 2Results postedReport a problem
• Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results postedReport a problem
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain TumorsCompletedNCT03387020Phase 1Results postedReport a problem
• LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPCCompletedNCT02494921Phase 1/2Results postedReport a problem
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results postedReport a problem
• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2Results postedReport a problem
• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant MelanomaCompletedNCT01781572Phase 1/2Results postedReport a problem
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedNCT01777776Phase 1/2Results postedReport a problem
• A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsCompletedNCT01543698Phase 1/2Results postedReport a problem
• Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptCompletedNCT07487129Phase 4Report a problem
• Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerActive, not recruitingNCT07130643Phase 2Report a problem
• Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeWithdrawnNCT05691400Phase 4Report a problem
• Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer PatientsStatus unknownNCT05670054Phase 3Report a problem
• Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsTerminatedNCT05429502Phase 1Report a problem
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2Report a problem
• Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast CancerWithdrawnNCT05244434Not applicableReport a problem
• Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeTerminatedNCT05207709Phase 3Report a problem
• Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and LetrozoleCompletedNCT05163106Phase 2Report a problem
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
• Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingNCT03740334Phase 1Report a problem
• Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineCompletedNCT03462251Phase 3Report a problem
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsCompletedNCT03434262Phase 1Report a problem
• Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingNCT03425838Phase 3Report a problem
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)CompletedNCT03355794Phase 1Report a problem
• Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.Active, not recruitingNCT03283384Phase 2Report a problem
• Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.CompletedNCT03248427Phase 2Report a problem
• Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT03237390Phase 1Report a problem
• Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 2Report a problem
• Ribociclib and Bicalutamide in AR+ TNBCActive, not recruitingNCT03090165Phase 1/2Report a problem
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT03008408Phase 2Report a problem
• Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic MelanomaCompletedNCT02645149Phase 2Report a problem
• Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisCompletedNCT02370706Phase 1Report a problem
• Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With LiposarcomaCompletedNCT02343172Phase 1Report a problem
• A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerCompletedNCT02333370Phase 1Report a problem
• Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast CancerCompletedNCT02088684Phase 1Report a problem
• DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).CompletedNCT02035813Phase 2Report a problem
• Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingNCT01872260Phase 1/2Report a problem

← Ribociclib